Intravenous Needles Market by Product Type (Hypodermic Needles, Infusion Needles), Material (Nickel Plated, Plastic, Stainless Steel), Gauge, Sales Channel, Application, End User - Global Forecast 2025-2032
Description
The Intravenous Needles Market was valued at USD 2.14 billion in 2024 and is projected to grow to USD 2.28 billion in 2025, with a CAGR of 6.43%, reaching USD 3.53 billion by 2032.
A concise overview of how clinical priorities, evolving care settings, and device innovation are reshaping demand and expectations for intravenous needle solutions
Intravenous needles are a foundational component of modern healthcare delivery, underpinning everything from routine blood collection to high-acuity infusion therapies. Their performance and design have a direct bearing on patient safety, clinician efficiency, and the economics of care pathways. Over the last several years, clinical practice has placed escalating emphasis on sharps safety, infection prevention, and user ergonomics, prompting manufacturers and healthcare providers to reevaluate product portfolios and procurement standards.
At the same time, care settings have diversified. Delivery of therapies has shifted beyond the inpatient ward to ambulatory surgery centers, emergency care hubs, clinics, and the home environment, creating nuanced requirements for needle design, packaging, and distribution. Parallel advances in materials science and device engineering have enabled safety innovations and more sophisticated infusion interfaces, which in turn influence clinician training, logistics, and device adoption pathways. This introduction frames the landscape by highlighting how clinical priorities, regulatory expectations, and operational pressures converge to shape demand for hypodermic and infusion needle solutions.
How safety design mandates, homecare expansion, supply chain digitalization, and sustainability commitments are fundamentally transforming the intravenous needle ecosystem
The last decade has witnessed transformative shifts that are redefining the intravenous needle landscape across technology, care delivery, and commercial channels. Safety-engineered designs have moved from a compliance checkbox to a core product differentiator, with both passive and active safety mechanisms now expected by procurement committees to reduce needlestick incidents and associated regulatory exposures. Concurrently, the migration of complex therapies into ambulatory and homecare environments has raised the bar for usability, packaging, and instructions for non-specialist caregivers, prompting manufacturers to adapt form factors and training supports.
Supply chain dynamics and digitalization are also reshaping the industry. Manufacturers have invested in traceability, serialization, and e-commerce-friendly packaging to meet the needs of institutional contracts and direct-to-customer channels alike. Sustainability considerations have begun to influence material selection and waste management strategies, pushing product development toward lower-impact plastics and sterilization processes with reduced environmental footprints. Finally, regulatory emphasis on post-market surveillance and clinician-reported outcomes is prompting closer collaboration between device makers and healthcare institutions to capture real-world performance data and accelerate iterative design improvements.
Assessment of how 2025 tariff measures prompted supply chain diversification, procurement recalibration, and manufacturing adjustments across the intravenous needle sector
United States tariff adjustments in 2025 introduced an additional layer of complexity to procurement and manufacturing strategies for medical device stakeholders. The cumulative effect intensified cost pressure for devices and components that rely on international inputs, particularly precision stainless steel, specialized polymers, and ancillary packaging materials. Procurement teams responded by reassessing total landed cost versus unit price, shifting sourcing strategies toward geographically diversified suppliers and exploring nearshoring options to mitigate customs exposure and lead-time variability.
Beyond immediate cost considerations, tariffs influenced supplier relationships and investment decisions. Some manufacturers accelerated vertical integration to secure critical feedstocks or began qualifying alternative materials that offered similar clinical performance but different supply footprints. Regulatory compliance and documentation burdens increased for import-dependent product lines, prompting many companies to enhance customs-management capabilities and scenario planning. Ultimately, the tariff environment underscored the need for resilient supply chains, strategic inventory policies, and closer alignment between commercial pricing strategies and procurement risk management.
A comprehensive segmentation analysis revealing clinical and commercial priorities across product types, end-users, applications, materials, gauges, and sales channels
Insights drawn from detailed segmentation illuminate where clinical demand and commercial opportunity intersect across product, end-user, application, material, gauge, and sales-channel dimensions. When examined by product type, the landscape differentiates between hypodermic needles and infusion needles, with hypodermic variants spanning conventional, insulin-specific, and safety-enhanced devices-safety models further dividing into active and passive approaches-and infusion solutions encompassing over-the-needle catheters as well as winged infusion tips, with over-the-needle designs split between central venous and peripheral catheter applications and winged tips available in multi-use and single-use configurations. This granularity highlights design constraints and regulatory considerations unique to each subsegment, such as the stability requirements for central venous catheters versus the disposability expectations for single-use winged tips.
End-user segmentation provides additional clarity on demand drivers and purchasing behavior, with use settings ranging from ambulatory environments that include emergency and surgery centers, to clinics subdivided into diagnostic and specialty facilities, to homecare situations covering chronic and post-operative care, and hospital environments differentiated into private and public institutions. Each setting exerts distinct requirements on packaging unit counts, clinician training, and sterilization standards. Application-based segmentation-blood sampling with capillary and venous approaches, chemotherapy with intrathecal and intravenous routes, and drug administration across bolus injection and continuous infusion-maps clinical workflows to specific product features such as needle gauge, flow dynamics, and safety locking mechanisms. Material considerations separate nickel-plated, plastic, and stainless-steel options, with plastics further delineated into polypropylene and PVC choices and stainless-steel into medical and surgical grades, which in turn affect sterilizability, biocompatibility, and manufacturing cost. Gauge differentiation across fine, medium, and thick categories aligns directly with clinical application and patient comfort, while sales-channel segmentation distinguishes direct sales arrangements-ranging from institutional contracts to on-site engagements-from distributor networks that include retail pharmacies and wholesalers, and e-commerce pathways encompassing both B2B and B2C fulfillment models. Taken together, these segmentation lenses reveal where manufacturers should prioritize investments in design, regulatory evidence, and channel-specific marketing to address the nuanced needs of clinicians, payers, and patients.
How regional regulatory frameworks, procurement norms, and care-delivery models across the Americas, Europe Middle East & Africa, and Asia-Pacific are shaping product demand and supply strategies
Regional dynamics shape adoption patterns, regulatory expectations, and supply chain design in distinct ways across the Americas, Europe Middle East & Africa, and Asia-Pacific markets. In the Americas, procurement tends to emphasize compliance with stringent safety and reporting standards, with a strong focus on reducing needlestick injuries and optimizing clinician workflows; this drives demand for safety-engineered hypodermic devices and advanced infusion catheters tailored for high-volume institutional use. Private hospital purchasing behaviors often prioritize integrated contracting arrangements and value-added services such as clinician training programs and post-market support.
In Europe, Middle East & Africa, regulatory harmonization efforts alongside diverse healthcare delivery models create both opportunities and complexities. While some markets favor centralized procurement and standardized device lists, others require nuanced product adaptations to meet local clinical protocols and infrastructure constraints. Stakeholders in this region increasingly prioritize environmental impact and lifecycle considerations when evaluating materials and packaging. Asia-Pacific markets are characterized by rapid adoption of outpatient and home-based care models, significant manufacturing capacity, and an expanding role for domestic suppliers. Cost-sensitive procurement combined with growing clinical sophistication has encouraged manufacturers to offer tiered product portfolios that balance affordability with improved safety and ergonomic features. Across all regions, cross-border logistics, trade policy shifts, and regional supply chain resilience remain dominant themes shaping strategic planning.
Insights into competitive positioning, manufacturing resilience, regulatory readiness, and distribution strategies that define leading firms in the intravenous needle landscape
Competitive dynamics in the intravenous needle sector are defined by a mixture of product innovation, manufacturing scale, regulatory capabilities, and channel partnerships. Leading manufacturers differentiate through safety features and portfolio breadth that span hypodermic to advanced infusion systems, while a cohort of specialized firms focuses on high-precision components and catheter technologies. Many organizations are expanding capabilities through targeted acquisitions and strategic alliances to fill gaps in sterilization, polymer expertise, or digital traceability, and to accelerate time-to-market for safety-engineered devices.
Operational excellence remains a critical determinant of competitiveness. Companies that have invested in lean manufacturing, ISO-compliant quality management systems, and validated supply chains for medical-grade stainless steel and polymer compounds can respond more quickly to procurement tenders and regulatory inquiries. Similarly, firms that integrate clinical evidence generation into product development-partnering with hospitals and clinical research organizations to capture real-world usability and safety data-achieve stronger credibility with institutional buyers. Distribution strategies also matter; suppliers that balance institutional contracting with e-commerce capabilities and robust distributor networks tend to reach a broader cross-section of end users, from high-volume hospitals to decentralized homecare channels. Finally, companies that proactively address sustainability and end-of-life disposal concerns gain differentiated positioning as healthcare systems place growing emphasis on environmental stewardship.
Practical and high-impact recommendations for manufacturers, suppliers, and purchasers to strengthen safety, resilience, and commercial performance in intravenous needle portfolios
Industry leaders should adopt a holistic strategy that aligns product innovation with supply chain resilience and customer-centric go-to-market models. First, prioritize safety by investing in both passive and active safety technologies and ensuring clinical validation through targeted usability studies in representative care settings. This not only reduces occupational risk but also strengthens procurement narratives during tender evaluations. Second, pursue material and process diversification to reduce exposure to single-source inputs and tariff-driven cost volatility; qualifying alternate polymer grades and establishing secondary suppliers for critical stainless steel components will provide operational flexibility.
Commercially, balance direct institutional engagement with a robust distributor and e-commerce strategy to address the full spectrum of end users from hospitals to homecare patients. Enhance value propositions by bundling clinician training, device disposal solutions, and post-market surveillance services. On the operational side, strengthen serialization and traceability capabilities and implement advanced inventory analytics to optimize safety stock without inflating holding costs. Lastly, incorporate sustainability metrics into product roadmaps to align with payer and regulatory expectations, while maintaining rigorous quality systems and documentation to expedite regulatory clearances and institutional adoption.
A transparent, multi-method research approach combining secondary evidence, targeted primary interviews, and scenario analysis to ensure robust, actionable insights for stakeholders
This research combines multi-sourced secondary analysis with primary stakeholder engagement to ensure balanced, verifiable insights. Secondary work included review of regulatory guidance, clinical literature, sterilization and materials science references, and procurement best practices to establish a factual baseline for device features, clinical workflows, and policy trends. Primary research entailed structured interviews and targeted consultations with clinicians, procurement leads, manufacturing operations managers, and supply chain executives to capture experiential perspectives on usability, sourcing constraints, and adoption barriers.
Analytical techniques included segmentation mapping to align product attributes with end-user needs, supply chain scenario analysis to evaluate tariff and logistics impacts, and qualitative synthesis of company strategies and clinical adoption pathways. Data triangulation was applied to reconcile differing source perspectives and validate thematic findings. Where proprietary client requests shaped specific lines of inquiry, the methodology allowed for customized deep dives, including supplier audits and tender analysis. Limitations include variability in local procurement practices and evolving regulatory updates; consequently, readers should consider this study as a directional, evidence-based foundation to inform strategy rather than a substitute for localized due diligence.
A strategic synthesis emphasizing safety, supply resilience, and targeted investments in design and commercialization to secure clinical adoption and operational efficiency
The intravenous needle landscape is at an inflection point where safety expectations, diversified care settings, and supply chain dynamics converge to demand strategic adaptation. Manufacturers that integrate validated safety mechanisms, material flexibility, and evidence-generation into product development will be better positioned to meet the needs of hospitals, clinics, ambulatory centers, and the growing homecare environment. Procurement and clinical teams should emphasize total cost of ownership, clinician ergonomics, and disposal pathways when evaluating product options, while also accounting for tariff-driven supply risk and regional regulatory nuances.
Looking ahead, success will favor organizations that marry product excellence with resilient operations and thoughtful commercialization. By prioritizing safety, reliability, and supply-chain transparency-while embracing digital channels and sustainability commitments-stakeholders can reduce clinical risk, improve patient experience, and create durable competitive advantage. The study concludes that targeted investments in design, procurement agility, and clinician engagement are the most practical levers to drive adoption and operational efficiency across the intravenous needle ecosystem.
Note: PDF & Excel + Online Access - 1 Year
A concise overview of how clinical priorities, evolving care settings, and device innovation are reshaping demand and expectations for intravenous needle solutions
Intravenous needles are a foundational component of modern healthcare delivery, underpinning everything from routine blood collection to high-acuity infusion therapies. Their performance and design have a direct bearing on patient safety, clinician efficiency, and the economics of care pathways. Over the last several years, clinical practice has placed escalating emphasis on sharps safety, infection prevention, and user ergonomics, prompting manufacturers and healthcare providers to reevaluate product portfolios and procurement standards.
At the same time, care settings have diversified. Delivery of therapies has shifted beyond the inpatient ward to ambulatory surgery centers, emergency care hubs, clinics, and the home environment, creating nuanced requirements for needle design, packaging, and distribution. Parallel advances in materials science and device engineering have enabled safety innovations and more sophisticated infusion interfaces, which in turn influence clinician training, logistics, and device adoption pathways. This introduction frames the landscape by highlighting how clinical priorities, regulatory expectations, and operational pressures converge to shape demand for hypodermic and infusion needle solutions.
How safety design mandates, homecare expansion, supply chain digitalization, and sustainability commitments are fundamentally transforming the intravenous needle ecosystem
The last decade has witnessed transformative shifts that are redefining the intravenous needle landscape across technology, care delivery, and commercial channels. Safety-engineered designs have moved from a compliance checkbox to a core product differentiator, with both passive and active safety mechanisms now expected by procurement committees to reduce needlestick incidents and associated regulatory exposures. Concurrently, the migration of complex therapies into ambulatory and homecare environments has raised the bar for usability, packaging, and instructions for non-specialist caregivers, prompting manufacturers to adapt form factors and training supports.
Supply chain dynamics and digitalization are also reshaping the industry. Manufacturers have invested in traceability, serialization, and e-commerce-friendly packaging to meet the needs of institutional contracts and direct-to-customer channels alike. Sustainability considerations have begun to influence material selection and waste management strategies, pushing product development toward lower-impact plastics and sterilization processes with reduced environmental footprints. Finally, regulatory emphasis on post-market surveillance and clinician-reported outcomes is prompting closer collaboration between device makers and healthcare institutions to capture real-world performance data and accelerate iterative design improvements.
Assessment of how 2025 tariff measures prompted supply chain diversification, procurement recalibration, and manufacturing adjustments across the intravenous needle sector
United States tariff adjustments in 2025 introduced an additional layer of complexity to procurement and manufacturing strategies for medical device stakeholders. The cumulative effect intensified cost pressure for devices and components that rely on international inputs, particularly precision stainless steel, specialized polymers, and ancillary packaging materials. Procurement teams responded by reassessing total landed cost versus unit price, shifting sourcing strategies toward geographically diversified suppliers and exploring nearshoring options to mitigate customs exposure and lead-time variability.
Beyond immediate cost considerations, tariffs influenced supplier relationships and investment decisions. Some manufacturers accelerated vertical integration to secure critical feedstocks or began qualifying alternative materials that offered similar clinical performance but different supply footprints. Regulatory compliance and documentation burdens increased for import-dependent product lines, prompting many companies to enhance customs-management capabilities and scenario planning. Ultimately, the tariff environment underscored the need for resilient supply chains, strategic inventory policies, and closer alignment between commercial pricing strategies and procurement risk management.
A comprehensive segmentation analysis revealing clinical and commercial priorities across product types, end-users, applications, materials, gauges, and sales channels
Insights drawn from detailed segmentation illuminate where clinical demand and commercial opportunity intersect across product, end-user, application, material, gauge, and sales-channel dimensions. When examined by product type, the landscape differentiates between hypodermic needles and infusion needles, with hypodermic variants spanning conventional, insulin-specific, and safety-enhanced devices-safety models further dividing into active and passive approaches-and infusion solutions encompassing over-the-needle catheters as well as winged infusion tips, with over-the-needle designs split between central venous and peripheral catheter applications and winged tips available in multi-use and single-use configurations. This granularity highlights design constraints and regulatory considerations unique to each subsegment, such as the stability requirements for central venous catheters versus the disposability expectations for single-use winged tips.
End-user segmentation provides additional clarity on demand drivers and purchasing behavior, with use settings ranging from ambulatory environments that include emergency and surgery centers, to clinics subdivided into diagnostic and specialty facilities, to homecare situations covering chronic and post-operative care, and hospital environments differentiated into private and public institutions. Each setting exerts distinct requirements on packaging unit counts, clinician training, and sterilization standards. Application-based segmentation-blood sampling with capillary and venous approaches, chemotherapy with intrathecal and intravenous routes, and drug administration across bolus injection and continuous infusion-maps clinical workflows to specific product features such as needle gauge, flow dynamics, and safety locking mechanisms. Material considerations separate nickel-plated, plastic, and stainless-steel options, with plastics further delineated into polypropylene and PVC choices and stainless-steel into medical and surgical grades, which in turn affect sterilizability, biocompatibility, and manufacturing cost. Gauge differentiation across fine, medium, and thick categories aligns directly with clinical application and patient comfort, while sales-channel segmentation distinguishes direct sales arrangements-ranging from institutional contracts to on-site engagements-from distributor networks that include retail pharmacies and wholesalers, and e-commerce pathways encompassing both B2B and B2C fulfillment models. Taken together, these segmentation lenses reveal where manufacturers should prioritize investments in design, regulatory evidence, and channel-specific marketing to address the nuanced needs of clinicians, payers, and patients.
How regional regulatory frameworks, procurement norms, and care-delivery models across the Americas, Europe Middle East & Africa, and Asia-Pacific are shaping product demand and supply strategies
Regional dynamics shape adoption patterns, regulatory expectations, and supply chain design in distinct ways across the Americas, Europe Middle East & Africa, and Asia-Pacific markets. In the Americas, procurement tends to emphasize compliance with stringent safety and reporting standards, with a strong focus on reducing needlestick injuries and optimizing clinician workflows; this drives demand for safety-engineered hypodermic devices and advanced infusion catheters tailored for high-volume institutional use. Private hospital purchasing behaviors often prioritize integrated contracting arrangements and value-added services such as clinician training programs and post-market support.
In Europe, Middle East & Africa, regulatory harmonization efforts alongside diverse healthcare delivery models create both opportunities and complexities. While some markets favor centralized procurement and standardized device lists, others require nuanced product adaptations to meet local clinical protocols and infrastructure constraints. Stakeholders in this region increasingly prioritize environmental impact and lifecycle considerations when evaluating materials and packaging. Asia-Pacific markets are characterized by rapid adoption of outpatient and home-based care models, significant manufacturing capacity, and an expanding role for domestic suppliers. Cost-sensitive procurement combined with growing clinical sophistication has encouraged manufacturers to offer tiered product portfolios that balance affordability with improved safety and ergonomic features. Across all regions, cross-border logistics, trade policy shifts, and regional supply chain resilience remain dominant themes shaping strategic planning.
Insights into competitive positioning, manufacturing resilience, regulatory readiness, and distribution strategies that define leading firms in the intravenous needle landscape
Competitive dynamics in the intravenous needle sector are defined by a mixture of product innovation, manufacturing scale, regulatory capabilities, and channel partnerships. Leading manufacturers differentiate through safety features and portfolio breadth that span hypodermic to advanced infusion systems, while a cohort of specialized firms focuses on high-precision components and catheter technologies. Many organizations are expanding capabilities through targeted acquisitions and strategic alliances to fill gaps in sterilization, polymer expertise, or digital traceability, and to accelerate time-to-market for safety-engineered devices.
Operational excellence remains a critical determinant of competitiveness. Companies that have invested in lean manufacturing, ISO-compliant quality management systems, and validated supply chains for medical-grade stainless steel and polymer compounds can respond more quickly to procurement tenders and regulatory inquiries. Similarly, firms that integrate clinical evidence generation into product development-partnering with hospitals and clinical research organizations to capture real-world usability and safety data-achieve stronger credibility with institutional buyers. Distribution strategies also matter; suppliers that balance institutional contracting with e-commerce capabilities and robust distributor networks tend to reach a broader cross-section of end users, from high-volume hospitals to decentralized homecare channels. Finally, companies that proactively address sustainability and end-of-life disposal concerns gain differentiated positioning as healthcare systems place growing emphasis on environmental stewardship.
Practical and high-impact recommendations for manufacturers, suppliers, and purchasers to strengthen safety, resilience, and commercial performance in intravenous needle portfolios
Industry leaders should adopt a holistic strategy that aligns product innovation with supply chain resilience and customer-centric go-to-market models. First, prioritize safety by investing in both passive and active safety technologies and ensuring clinical validation through targeted usability studies in representative care settings. This not only reduces occupational risk but also strengthens procurement narratives during tender evaluations. Second, pursue material and process diversification to reduce exposure to single-source inputs and tariff-driven cost volatility; qualifying alternate polymer grades and establishing secondary suppliers for critical stainless steel components will provide operational flexibility.
Commercially, balance direct institutional engagement with a robust distributor and e-commerce strategy to address the full spectrum of end users from hospitals to homecare patients. Enhance value propositions by bundling clinician training, device disposal solutions, and post-market surveillance services. On the operational side, strengthen serialization and traceability capabilities and implement advanced inventory analytics to optimize safety stock without inflating holding costs. Lastly, incorporate sustainability metrics into product roadmaps to align with payer and regulatory expectations, while maintaining rigorous quality systems and documentation to expedite regulatory clearances and institutional adoption.
A transparent, multi-method research approach combining secondary evidence, targeted primary interviews, and scenario analysis to ensure robust, actionable insights for stakeholders
This research combines multi-sourced secondary analysis with primary stakeholder engagement to ensure balanced, verifiable insights. Secondary work included review of regulatory guidance, clinical literature, sterilization and materials science references, and procurement best practices to establish a factual baseline for device features, clinical workflows, and policy trends. Primary research entailed structured interviews and targeted consultations with clinicians, procurement leads, manufacturing operations managers, and supply chain executives to capture experiential perspectives on usability, sourcing constraints, and adoption barriers.
Analytical techniques included segmentation mapping to align product attributes with end-user needs, supply chain scenario analysis to evaluate tariff and logistics impacts, and qualitative synthesis of company strategies and clinical adoption pathways. Data triangulation was applied to reconcile differing source perspectives and validate thematic findings. Where proprietary client requests shaped specific lines of inquiry, the methodology allowed for customized deep dives, including supplier audits and tender analysis. Limitations include variability in local procurement practices and evolving regulatory updates; consequently, readers should consider this study as a directional, evidence-based foundation to inform strategy rather than a substitute for localized due diligence.
A strategic synthesis emphasizing safety, supply resilience, and targeted investments in design and commercialization to secure clinical adoption and operational efficiency
The intravenous needle landscape is at an inflection point where safety expectations, diversified care settings, and supply chain dynamics converge to demand strategic adaptation. Manufacturers that integrate validated safety mechanisms, material flexibility, and evidence-generation into product development will be better positioned to meet the needs of hospitals, clinics, ambulatory centers, and the growing homecare environment. Procurement and clinical teams should emphasize total cost of ownership, clinician ergonomics, and disposal pathways when evaluating product options, while also accounting for tariff-driven supply risk and regional regulatory nuances.
Looking ahead, success will favor organizations that marry product excellence with resilient operations and thoughtful commercialization. By prioritizing safety, reliability, and supply-chain transparency-while embracing digital channels and sustainability commitments-stakeholders can reduce clinical risk, improve patient experience, and create durable competitive advantage. The study concludes that targeted investments in design, procurement agility, and clinician engagement are the most practical levers to drive adoption and operational efficiency across the intravenous needle ecosystem.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
199 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Rising demand for safety-engineered intravenous needles to reduce needlestick injuries
- 5.2. Integration of antimicrobial coatings on intravenous needles to prevent catheter-related infections
- 5.3. Growing adoption of eco-friendly and biodegradable materials in needle manufacturing to reduce medical waste
- 5.4. Increasing customization of needle gauge sizes and lengths to support diverse patient demographics
- 5.5. Advances in autologous blood sampling-compatible intravenous needles for point-of-care diagnostics
- 5.6. Expansion of needleless connectors and integrated IV systems to streamline infusion therapy workflows
- 5.7. Regulatory push for single-use intravenous needle systems to enhance sterility and patient safety
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Intravenous Needles Market, by Product Type
- 8.1. Hypodermic Needles
- 8.1.1. Conventional Needles
- 8.1.2. Insulin Needles
- 8.1.3. Safety Needles
- 8.1.3.1. Active Safety
- 8.1.3.2. Passive Safety
- 8.2. Infusion Needles
- 8.2.1. Over The Needle Catheters
- 8.2.1.1. Central Venous Catheters
- 8.2.1.2. Peripheral Catheters
- 8.2.2. Winged Infusion Tips
- 8.2.2.1. Multi Use
- 8.2.2.2. Single Use
- 9. Intravenous Needles Market, by Material
- 9.1. Nickel Plated
- 9.2. Plastic
- 9.2.1. Polypropylene
- 9.2.2. PVC
- 9.3. Stainless Steel
- 9.3.1. Medical Grade
- 9.3.2. Surgical Grade
- 10. Intravenous Needles Market, by Gauge
- 10.1. Fine Gauge
- 10.2. Medium Gauge
- 10.3. Thick Gauge
- 11. Intravenous Needles Market, by Sales Channel
- 11.1. Direct Sales
- 11.1.1. Institutional Contracts
- 11.1.2. On Site Sales
- 11.2. Distributors
- 11.3. E Commerce
- 12. Intravenous Needles Market, by Application
- 12.1. Blood Sampling
- 12.1.1. Capillary Sampling
- 12.1.2. Venous Sampling
- 12.2. Chemotherapy
- 12.2.1. Intrathecal Administration
- 12.2.2. Intravenous Chemotherapy
- 12.3. Drug Administration
- 12.3.1. Bolus Injection
- 12.3.2. Continuous Infusion
- 13. Intravenous Needles Market, by End User
- 13.1. Ambulatory
- 13.1.1. Emergency Centers
- 13.1.2. Surgery Centers
- 13.2. Clinics
- 13.2.1. Diagnostic Clinics
- 13.2.2. Specialty Clinics
- 13.3. Homecare
- 13.3.1. Chronic Care
- 13.3.2. Post Operative Care
- 13.4. Hospitals
- 13.4.1. Private Hospitals
- 13.4.2. Public Hospitals
- 14. Intravenous Needles Market, by Region
- 14.1. Americas
- 14.1.1. North America
- 14.1.2. Latin America
- 14.2. Europe, Middle East & Africa
- 14.2.1. Europe
- 14.2.2. Middle East
- 14.2.3. Africa
- 14.3. Asia-Pacific
- 15. Intravenous Needles Market, by Group
- 15.1. ASEAN
- 15.2. GCC
- 15.3. European Union
- 15.4. BRICS
- 15.5. G7
- 15.6. NATO
- 16. Intravenous Needles Market, by Country
- 16.1. United States
- 16.2. Canada
- 16.3. Mexico
- 16.4. Brazil
- 16.5. United Kingdom
- 16.6. Germany
- 16.7. France
- 16.8. Russia
- 16.9. Italy
- 16.10. Spain
- 16.11. China
- 16.12. India
- 16.13. Japan
- 16.14. Australia
- 16.15. South Korea
- 17. Competitive Landscape
- 17.1. Market Share Analysis, 2024
- 17.2. FPNV Positioning Matrix, 2024
- 17.3. Competitive Analysis
- 17.3.1. Abcam Inc.
- 17.3.2. Advin Health Care
- 17.3.3. Argon Medical Devices, Inc.
- 17.3.4. B. Braun SE
- 17.3.5. Becton, Dickinson and Company
- 17.3.6. Bio-Rad Laboratories, Inc.
- 17.3.7. Biomedical Srl
- 17.3.8. Boston Scientific Corporation
- 17.3.9. Cardinal Health, Inc.
- 17.3.10. Cook Group Incorporated
- 17.3.11. Freudenberg Medical, LLC
- 17.3.12. Medtronic PLC
- 17.3.13. Merck KGaA
- 17.3.14. Novo Nordisk A/S
- 17.3.15. Olympus Corporation
- 17.3.16. PerkinElmer, Inc.
- 17.3.17. QIAGEN
- 17.3.18. Shimadzu Corporation
- 17.3.19. Siemens AG
- 17.3.20. Smith & Nephew PLC
- 17.3.21. Stryker Corporation
- 17.3.22. Teleflex Incorporated.
- 17.3.23. Thermo Fisher Scientific Inc.
- 17.3.24. Volkmann MedizinTechnik GmbH
- 17.3.25. Zhejiang Longde Pharmaceutical Co., Ltd.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
